Program
elisrasib
Its studies are led by D3 Bio (Wuxi).
Furthest: phase 2, since May 25, 20222 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| D3 Bio (Wuxi) | 21 open or running | phase 2since May 25, 2022 | May 25, 2022 | Apr 2027phase 2 · NCT05410145 |
Also a collaborator on its studies: Fortrea.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 25, 2022First study: phase 2 study in KRAS P.G12CFirst studyNCT05410145 · 442 planned · United States, Australia, China and more
- Jul 10, 2025Phase 1 study in Healthy Adult VolunteersNCT07093398 · 26 enrolled · Australia
Ahead
- Apr 2027Primary completion: phase 2 study in KRAS P.G12CNCT05410145
TargetBeta
KRAS →read by rule
“An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07093398Healthy Adult Volunteers · Australia | 1 | Completed | Nov 12, 2025 | 26 |
| NCT05410145KRAS P.G12C · United States, Australia, China and more | 2 | Recruiting | Apr 2027 | 442 |
How it is read
Names in the registry
- “D3S-001”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.